BIOMAT Database Logo BIOMAT Database Logo

Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. 2006

Patricia T Ting, and John Y Koo
Department of Dermatology, University of California-San Francisco (UCSF), San Francisco, California, USA. patriciating@gmail.com

BACKGROUND Etanercept (Enbrel, Amgen, Thousand Oaks, CA), a soluble p75 tumor necrosis factor receptor:FC (TNFR:FC) fusion protein for plasma cytokines, specifically tumor necrosis factor-alpha (TNF-alpha), is used in the treatment of immune-mediated rheumatic diseases. To our knowledge, the use of etanercept in patients with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) is relatively uncommon. OBJECTIVE The main purpose of this short review is to examine the safety of etanercept in patients with HIV/AIDS. METHODS A Medline search was conducted using the keywords etanercept and HIV and/or AIDS for any published articles between 1966 to the present (September 2004). RESULTS A case report, one case series, and one clinical trial pertained to the use of etanercept in HIV patients. No reports were found on the use of etanercept in AIDS. In addition, two case reports were found documenting the use of infliximab in HIV patients. CONCLUSIONS Preliminary reports indicate that the administration of etanercept does not appear to increase the morbidity or mortality rates in HIV. The inhibition of TNF-alpha may actually improve the symptoms of HIV/AIDS-associated aphthous ulcers, cachexia, dementia, fatigue, and fever, as well as help manage concomitant rheumatic diseases and psoriasis. CONCLUSIONS The use of etanercept shows promise for applications in disease management in patients with HIV/AIDS. Continued research efforts are necessary to establish the long-term safety and efficacy of etanercept and other biologic agents in this patient population.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068800 Etanercept A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. Enbrel,Erelzi,Etanercept-szzs,Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,TNF Receptor Type II-IgG Fusion Protein,TNFR-Fc Fusion Protein,TNR 001,TNR-001,TNT Receptor Fusion Protein,TNTR-Fc,Fusion Protein, TNFR-Fc,Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein,TNF Receptor Type II IgG Fusion Protein,TNFR Fc Fusion Protein,TNR001
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018124 Receptors, Tumor Necrosis Factor Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells. Cachectin Receptors,TNF Receptors,Tumor Necrosis Factor Receptors,Receptors, Cachectin,Receptors, TNF,TNF Receptor,Tumor Necrosis Factor Receptor,Receptor, TNF

Related Publications

Patricia T Ting, and John Y Koo
[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)].
January 1995, Ryoikibetsu shokogun shirizu,
Patricia T Ting, and John Y Koo
[Acquired immunodeficiency syndrome (AIDS) and human immunodeficiency virus (HIV), and chemotherapeutic approaches to AIDS].
February 1988, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Patricia T Ting, and John Y Koo
[The human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) in New Caledonia].
January 1989, Medecine tropicale : revue du Corps de sante colonial,
Patricia T Ting, and John Y Koo
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) mortality in industrialized nations, 1987-1991.
August 1998, International journal of epidemiology,
Patricia T Ting, and John Y Koo
Appetite and nutrition in relation to human immunodeficiency virus (HIV) infection and acquired immunodeficiency virus syndrome (AIDS).
March 1994, The Proceedings of the Nutrition Society,
Patricia T Ting, and John Y Koo
The challenge of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in women and children.
April 1988, Fertility and sterility,
Patricia T Ting, and John Y Koo
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Risk (HIV/AIDS)-Taking Behavior and HIV/AIDS Knowledge With African-American Women.
December 2015, International journal of high risk behaviors & addiction,
Patricia T Ting, and John Y Koo
Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong.
April 2006, Hong Kong medical journal = Xianggang yi xue za zhi,
Patricia T Ting, and John Y Koo
Personality profile among Human Immunodeficiency Virus (HIV) positives and Acquired Immunodeficiency Syndrome (AIDS) patients of injecting drug users.
January 2007, Kathmandu University medical journal (KUMJ),
Patricia T Ting, and John Y Koo
[Pulmonary complications in acquired immunodeficiency syndrome (AIDS) and syndromes related to human immunodeficiency virus (HIV) infection].
December 1988, Giornale di clinica medica,
Copied contents to your clipboard!